Drug ID:Drug120
Drug Name:CE-224535
CID:11547499
DrugBank ID:DB12113
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NULL
Molecular Formula:C22H29ClN4O6
Molecular Weight:480.9 g/mol
Isomeric SMILES:COC[C@@H](CN1C(=O)C=NN(C1=O)C2=CC(=C(C=C2)Cl)C(=O)NCC3(CCCCCC3)O)O
Synonyms:CE-224535; 724424-43-5; UNII-T8B02RAU3C; T8B02RAU3C; CE 224,535; CE 224535; 2-chloro-N-[(1-hydroxycycloheptyl)methyl]-5-[4-[(2R)-2-hydroxy-3-methoxypropyl]-3,5-dioxo-1,2,4-triazin-2-yl]benzamide; 2-(4-Chloro-3-(3-(1-hydroxycycloheptyl)propanoyl)phenyl)-4-((2R)-2-hydroxy-3-methoxy-propyl)-1,2,4-triazine-3,5-dione; compound 3 [PMID: 21782426]; Benzamide, 2-chloro-5-(4,5-dihydro-4-((2R)-2-hydroxy-3-methoxypropyl)-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-n-((1-hydroxycycloheptyl)methyl)-
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt995 11547499 Ce-224535 5027 P2RX7 Homo sapiens (human) None
dt996 11547499 Ce-224535 5027 P2RX7 Homo sapiens (human) 21320518 CE 224,535 binds to and results in decreased activity of P2RX7 protein
dt997 11547499 Ce-224535 5027 P2RX7 Homo sapiens (human) 21565499 P2X purinoceptor 7 antagonist
dt998 11547499 Ce-224535 5027 P2RX7 Homo sapiens (human) 37713619 Antagonist
dt999 11547499 Ce-224535 5027 P2RX7 Homo sapiens (human) Antagonist
dt1000 11547499 Ce-224535 5027 P2RX7 Homo sapiens (human) 21565499 Antagonist
dt1001 11547499 Ce-224535 5027 P2RX7 Homo sapiens (human) Inhibitor

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT00989573 A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease PHASE2|PHASE3 COMPLETED Otsuka Pharmaceutical Co., Ltd. Crohn's Disease DRUG: Placebo|DRUG: OPC-6535|DRUG: OPC-6535 Details
NCT00317369 A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease PHASE2 TERMINATED Otsuka Pharmaceutical Co., Ltd. Crohn Disease DRUG: OPC-6535(Tetomilast) Details
NCT00317356 A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis PHASE2 TERMINATED Otsuka Pharmaceutical Co., Ltd. Colitis, Ulcerative DRUG: OPC-6535(Tetomilast) Details
NCT00092508 CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission PHASE3 COMPLETED Otsuka Pharmaceutical Development & Commercialization, Inc. Ulcerative Colitis DRUG: OPC-6535|DRUG: Asacol® Details
NCT00064454 FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis PHASE3 COMPLETED Otsuka Pharmaceutical Development & Commercialization, Inc. Ulcerative Colitis DRUG: OPC-6535 Tablets (drug) Details
NCT00064441 FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis PHASE3 COMPLETED Otsuka Pharmaceutical Development & Commercialization, Inc. Ulcerative Colitis DRUG: OPC-6535 Tablets (drug) Details
CTIS2023-508224-35-01 Analgesic effect of intravenous lidocaine and its mechanisms in patients suffering from chronic inflammatory bowel disease (IBD) with abdominal pain. PHASE2 Recruiting CHU De Liege Inflammatory Bowel disease;Therapeutic area: Dise… Product Name: Linisol 1 %, solution injectable, P… Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years PHASE3 RECRUITING Ardelyx Irritable Bowel Syndrome With Constipation (IBS-C) DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… Details
NCT05633706 Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis NULL RECRUITING Nimble Science Ltd. Irritable Bowel Syndrome|Crohn Disease|Celiac Dis… DEVICE: fluid biopsy capsule Details
NCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome PHASE3 RECRUITING Biocodex IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… Details
NCT05602116 ASC - Autism Study PHASE1 COMPLETED Cell to Cure ApS Autism Spectrum Disorder|Gastrointestinal Dysfunc… DRUG: Adipose tissue derived mesenchymal stromal/… Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05573685 Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training NA COMPLETED Click Therapeutics, Inc. Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… DEVICE: DiNaMo Study App|DEVICE: Placebo App Details
NCT05536440 A Study to Learn About Study Medicine Called PF-07261271 in Healthy People PHASE1 COMPLETED Pfizer Healthy DRUG: PF-07261271|DRUG: Placebo Details
NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease PHASE3 RECRUITING Eli Lilly and Company Crohn's Disease DRUG: Mirikizumab Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05466890 Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) PHASE2 ACTIVE_NOT_RECRUITING Palatin Technologies, Inc Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… DRUG: PL8177 Placebo|DRUG: PL8177 Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
2.0 ulcerative colitis A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib No abstract available Details

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S03 Anti-TNF agents Tumor necrosis factor infliximab; adalimumab; golimumab; certolizumab pegol TNF is produced by various immune and non-immune cells in t… Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations